Author: Gutierrez, MarÃa Del Mar; Mur, Isabel; Mateo, MarÃa Gracia; Vidal, Francesc; Domingo, Pere
Title: Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH) Cord-id: 7u4m0og5 Document date: 2021_2_26
ID: 7u4m0og5
Snippet: INTRODUCTION: When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. AREAS COVERED: Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART)
Document: INTRODUCTION: When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. AREAS COVERED: Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART) in preventing infection or reducing COVID-19 severity. They also discuss the pharmacological interventions for COVID-19 in PLWH. EXPERT OPINION: Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug–drug interactions of most corticosteroids and antiretroviral drugs.
Search related documents:
Co phrase search for related documents- acute respiratory failure and adjunctive therapy: 1, 2, 3, 4
- acute respiratory failure and administration avoid: 1
- acute respiratory failure and admission diagnosis: 1, 2, 3, 4
- acute respiratory failure and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory failure and liver decompensation: 1, 2, 3
- acute respiratory failure and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory failure and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute respiratory failure and liver injury risk: 1, 2, 3
- acute respiratory failure and lmwh weight heparin: 1, 2, 3, 4
- acute respiratory failure and long duration: 1, 2
- acute respiratory failure and long period: 1
- acute respiratory failure and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory failure and low incidence: 1, 2
- acute respiratory failure and low lymphocyte: 1, 2
- acute respiratory failure and low lymphocyte count: 1
- acute respiratory failure and low number: 1, 2
- acute respiratory failure and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute respiratory failure and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory failure and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
Co phrase search for related documents, hyperlinks ordered by date